T1	Participants 125 159	premenopausal early breast cancer:
T2	Participants 182 241	Austrian Breast and Colorectal Cancer Study Group Trial 12.
T3	Participants 511 754	Patients were premenopausal women who had undergone primary surgery for stage I/II estrogen-receptor-positive and/or progesterone-receptor-positive breast cancer with <10 positive lymph nodes, and were scheduled for standard goserelin therapy.
T4	Participants 759 875	1803 patients received goserelin (3.6 mg every 28 days) and were randomized to tamoxifen (20 mg/days) or anastrozole
